PURPOSE This short review aims to cover the more recent and promising developments of carbon-11 (11C) labeling radiochemistry and its utility in the production of novel radiopharmaceuticals, with special emphasis on methods that have the greatest potential to be translated for clinical positron emission tomography (PET) imaging. METHODS A survey of the literature was undertaken to identify ar...

The existence of the cyclotron & PET centre of UJV Rez, a.s., at Masaryk Memorial Cancer Institute allows the Masaryk Memorial Cancer Institute and RECAMO researchers to engage in the research, development and application of new radiopharmaceuticals including compounds labelled by short-living positron emitters (especially [11C]). Currently, a [11C]-labelled tracer, L-[methyl-11C]methionine, is...

UNLABELLED We studied the changing patterns of radiopharmaceutical use and the incidence of adverse events (AEs) to PET radiopharmaceuticals, non-PET radiopharmaceuticals, and adjunctive nonradioactive pharmaceuticals in nuclear medicine from 2007 to 2011. METHODS Fifteen academic institutions submitted quarterly reports of radiopharmaceutical use and AEs covering 2007-2011. RESULTS 1,024,1...

Positron Emission Tomography (PET) experienced accelerated development and has become an established method for medical research and clinical routine diagnostics on patient individualized basis. Development and availability of new radiopharmaceuticals specific for particular diseases is one of the driving forces of the expansion of clinical PET. The future development of the ⁶⁸Ga-radiopharmaceu...

The construction of the 68Ge/68Ga generator has increased application of radiopharmaceuticals labeled with this isotope in medicine. 68Ga-PET is widely employed in the management of neuroendocrine tumors but favorable chemistry with tri- and tetraaza-ring molecules has opened wide range of 68Ga application in other fields of PET imaging. This review covers the radiopharmaceuticals labeled with ...

The fields of molecular biology, immunology and genetics have generated many important developments that advance the understanding of the induction and progression of oncological, cardiological and neurological diseases as well as the identification of disease-associated molecules and drugs that specifically target diseased cells during therapy. These insights have triggered the development of ...

Purpose. To perform an overview about the role of positron emission tomography (PET) or PET/computed tomography (PET/CT) using different radiopharmaceuticals in recurrent medullary thyroid carcinoma (MTC) based on biochemical findings (increased tumor marker levels after primary surgery). Methods. A comprehensive literature search of studies published in PubMed/MEDLINE, Scopus, and Embase datab...

Until recently PET scanning has been available only at major universities or teaching hospitals possessing the necessary resources and expertise to operate a research PET facility. Most dedicated PET centers cost several millions of dollars, and include a cyclotron, a radiochemistry laboratory to synthesize PET radiopharmaceuticals, a multicrystal dedicated PET camera, advanced computer f...

Introduction In nuclear medicine, diagnostic imaging displays the metabolic function of the human body. The radiopharmaceuticals enable cancer imaging as unbound isotopes or simple compounds, non target tracers, target tracers and target cancer radiopharmaceuticals (1). Molecular imaging strategies of PET radiopharmaceuticals and combined technology of PET-CT have a major role in oncology today...

Positron emission tomography (PET) is a nuclear medicine imaging technique. Through the use of various radiopharmaceuticals, PET allows in vivo imaging of regional cerebral functions, including cerebral blood flow, molecular metabolism, and receptor binding capacity. PET is useful not only for diagnosis and therapeutic planning but also for neurological science research.